Introduction
============

Intravitreal injections of anti-VEGF agents have become a mainstay of treatment for exudative age-related macular degeneration (exAMD),[@b1-opth-9-773] diabetic macular edema,[@b2-opth-9-773] and retinal vein occlusion.[@b3-opth-9-773] The relative efficacy of anti-VEGF versus alternative therapies has resulted in millions of such injections being administered annually.

Bevacizumab (Hoffmann-La Roche, Basel, Switzerland) and ranibizumab (Hoffmann-La Roche) are two of the most studied anti-VEGF medications in clinical practice, having first shown efficacy in the treatment of exAMD in 2005.[@b4-opth-9-773]--[@b6-opth-9-773] These medications are frequently compared as a result of their similar mechanisms of action. Ranibizumab is a monoclonal antibody fragment directed against VEGF-A. It is US Food and Drug administration-approved for use in exAMD, diabetic macular edema, and macular edema associated with retinal vein occlusion, and is supplied directly to practices from the manufacturer in individual vials for intraocular use. Bevacizumab is a full monoclonal antibody against VEGF-A that is widely used off-label to treat these same diseases. Because it is not provided by the manufacturer in individual doses, it is routinely aliquoted into ready-to-use syringes by compounding pharmacies or at the institution of administration. Alternatively, a single manufacturer-supplied vial may be used for a single injection only. The latter option reduces the perceived cost--benefit advantage bevacizumab may hold over ranibizumab.

The most feared complication of intravitreal injections is endophthalmitis. The occurrence, ranging from roughly one case in 1,000 to one in 5,000, and characteristics of these infections are well documented,[@b7-opth-9-773]--[@b9-opth-9-773] but there are still many lingering questions regarding the best preventive strategies and the sources of the causative organisms. Recent outbreaks of endophthalmitis have occurred in Miami, Nashville, Minneapolis, Los Angeles, and New York.[@b10-opth-9-773],[@b11-opth-9-773] A large, multistate outbreak of fungal meningitis occurred in 2012, prompting a recall that included ophthalmologic drugs.[@b12-opth-9-773]

Sterile inflammation has also been linked to intraocular injections, with cases potentially occurring in clusters.[@b13-opth-9-773],[@b14-opth-9-773] The etiology of such episodes is varied, and when known may include contaminants, use of the incorrect medication, counterfeit medication, bacterial endotoxins, or temperature fluctuation.[@b15-opth-9-773],[@b16-opth-9-773]

It has been postulated that the use of bevacizumab may lead to an increased incidence of postinjection endophthalmitis as a result of the different manufacturing process and extra drug manipulation that occurs with compounding.[@b17-opth-9-773] Because prospective data with sufficient statistical power to address small differences in risk are lacking, we report the results of a literature review through November 2013 focusing on the reported occurrence and risk factors of endophthalmitis associated with these two anti-VEGF agents.

Materials and methods
=====================

A comprehensive Medline search was performed via PubMed on November 27, 2013 using the terms "bevacizumab" and "ranibizumab". English-language articles were screened by title and abstract for relevance before all exclusion criteria were applied. Papers were identified for possible inclusion if their abstracts described intravitreal injections of bevacizumab and/or ranibizumab in any context and encompassed five or more patients. Additionally, if any exclusion criteria were satisfied in the abstract, the article was not examined. Because of the scarcity of trials comparing bevacizumab to ranibizumab directly, this was not criteria for inclusion.[@b18-opth-9-773] Study references were also reviewed where appropriate to uncover other potential articles.

Articles regardless of type were considered if intravitreal bevacizumab and/or ranibizumab were used in the treatment of any nonpediatric ophthalmologic condition. Exclusion criteria were treatment with a separate invasive ocular procedure within 4 weeks, including concurrent injections or procedures, injection into eyes with silicone oil, failure to report injection numbers or complications, inclusion of fewer than five patients, and the exclusion of endophthalmitis as entry criteria. Separate articles reporting on the same patients were examined carefully, including comparison of articles by study date and institution, so that injections were not counted more than once.

Information was collected regarding the number of injections, indications, operative and perioperative techniques, endophthalmitis cases and culture results, country of origin, and year published. Particular attention was paid to the use of povidone iodine, postoperative antibiotics, masks, and lid speculums, as well as to whether injections were administered in operating suites versus an office setting.

All statistical analysis was completed using R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria). Statistical comparisons regarding types of studies as well as bacterial species were made with the Fisher exact test. An unadjusted relative risk (RR) and 95% confidence interval (CI) were constructed using a generalized linear model and Poisson distribution. An adjusted RR and 95% CI were constructed using a random-effect model using publication as a random effect as a way of adjusting for publication. Wald *P*-values were determined. A log-likelihood *P*-value is reported for the adjusted RR of endophthalmitis when comparing bevacizumab to ranibizumab. A similar analysis was done for the endophthalmitis risks (all, positive, and negative) by region (US versus Europe).

Risk of infection was calculated as number of cases of endophthalmitis relative to the number of injections. Because the percentage of endophthalmitis cases cultured was different between certain groups, a normalized risk of infection was calculated assuming the number of cultured cases reported matched the highest proportion of cases cultured in each category of analysis. No RRs were calculated for the adjusted risk of infection, because there was not enough information to distribute the additional cases over the appropriate studies.

Results
=======

The Medline search yielded 9,517 potential articles of interest. Abstracts were reviewed, and 1,531 articles were identified for possible inclusion. After exclusion criteria were applied, 534 studies remained for analysis, of which 281 were prospective studies. No prospective studies were specifically designed to assess the risk of endophthalmitis.

There were a total of 445,503 injections administered in the included studies, of which 176,124 (39.5%) were bevacizumab and 269,379 (60.5%) were ranibizumab. There was a significant difference in the types of studies reporting each drug, with 36,742 of 176,124 (20.9%) bevacizumab injections reported prospectively versus 114,135 of 269,379 (42.4%) ranibizumab injections (*P*\<0.0001, odds ratio 0.359, 95% CI 0.354--0.364, Fisher's exact test). Data reported from 42 countries were included ([Table S1](#SD2-opth-9-773){ref-type="supplementary-material"}). Indications for injections are summarized in [Table 1](#t1-opth-9-773){ref-type="table"}.

There was wide variation in the reporting of perioperative protocols, with many studies omitting the exact details of the injection procedures. With extremely rare exceptions, studies did not report perioperative measures that were not instituted. Preinjection povidone iodine was reported in 290 studies (54.3%), and was the most commonly reported variable perioperative condition. Postoperative antibiotic use was reported in 235 studies (44%), lid-speculum use in 136 studies (25.5%), operating room use in 78 studies (14.6%), and surgical mask use for the physician in 54 studies (10.1%). Bevacizumab and ranibizumab groups were similar in perioperative reporting ([Table 2](#t2-opth-9-773){ref-type="table"}), differing only slightly in the reporting of antibiotic use (*P*\<0.0001, adjusted RR 0.96, 95% CI 0.94--0.97).

There were 103 cases of endophthalmitis with bevacizumab injections, resulting in a risk of 0.058% (95% CI 0.048%--0.071%), and there were 79 cases with ranibizumab injections for a risk of 0.029% (95% CI 0.024%--0.037%). This difference was statistically significant using the random-effect model and a log-likelihood *P*-value (*P*=0.01, adjusted RR 1.59, 95% CI 1.11--2.29). The risk of endophthalmitis by year showed only minor variation (Figure S1). The risk was not significantly different either in retrospective versus prospective data (*P*=0.12, adjusted RR 1.59, 95% CI 0.84--3.03). None of the perioperative variables had an effect on endophthalmitis risk that reached statistical significance when considering all cases of endophthalmitis together ([Table 3](#t3-opth-9-773){ref-type="table"}), although this was not true when considering culture-positive and culture-negative cases separately ([Tables 4](#t4-opth-9-773){ref-type="table"} and [5](#t5-opth-9-773){ref-type="table"}). The reported use of postoperative antibiotics significantly increased the risk of culture-positive endophthalmitis (*P*=0.02, adjusted RR 2.7, 95% CI 1.06--7.14).

The total nonnormalized culture-positive and culture-negative occurrences of endophthalmitis of 172,991 injections in the US were 80 cases (0.046%, 95% CI 0.044%--0.058%), 22 cases (0.013%, 95% CI 0.009%--0.019%), and 55 cases (0.032%, 95% CI 0.024%--0.041%). In Europe, of 119,477 injections, the same subgroups had 33 cases (0.028%, 95% CI 0.02%--0.039%), eight cases (0.007%, 95% CI 0.003%--0.013%), and 13 cases (0.011%, 95% CI 0.006%--0.019%). None of these differences was statistically significant using the random-effect model ([Table 6](#t6-opth-9-773){ref-type="table"}).

Organisms cultured are shown in [Table 7](#t7-opth-9-773){ref-type="table"}. Streptococcal species accounted for nine of 54 culture-positive endophthalmitis cases (16.6%, 95% CI 9.02%--28.7%). In studies from the US, seven of 22 cases (31.8%, 95% CI 16.4%--52.7%) were due to streptococcal species versus three of 24 cases (12.5%, 95% CI 4.3%--31%) throughout the rest of the world (*P*=0.16, odds ratio 3.18, 95% CI 0.6--22.22, Fisher's exact test). There were no reported streptococcal species recovered in Europe or in studies reporting the use of a mask, although the latter sample size was small, comprising only 28,799 injections.

This analysis was repeated for prospective data only, and the results are shown in [Table 8](#t8-opth-9-773){ref-type="table"}. No factor was significantly associated with the overall risk of endophthalmitis. Additionally, there was not a significant difference in culture-positive or culture-negative endophthalmitis risk between bevacizumab and ranibizumab in this analysis.

Discussion
==========

Our understanding of the causative factors that underlie intravitreal injection-related endophthalmitis remains incomplete, despite the vast number of injections administered annually. Prospective analysis comparing the risk of endophthalmitis between different drugs or different injection techniques is problematic, because the rarity of events limits the statistical power of such studies. The purpose of the present review was to investigate these factors by combining all data published from the inception of bevacizumab and ranibizumab intraocular therapy.

There was a significantly higher risk of endophthalmitis related to bevacizumab (0.058%) compared with ranibizumab (0.029%). This difference was attributable to a greater risk of culture-negative cases in the bevacizumab group, while there was no statistically significant difference in culture-positive risk between the two groups. There was also no difference in overall, culture-positive, or culture-negative occurrence when considering prospectively reported data alone. Outbreaks of culture-positive endophthalmitis associated with bevacizumab have been reported,[@b10-opth-9-773],[@b11-opth-9-773] but the data presented here would indicate that such reports are an exception to the rule and are statistically insignificant, considering the vast amount of drugs used safely. Of course, endophthalmitis is always significant to the patients afflicted. An alternative explanation is that an increased risk of bevacizumab-related endophthalmitis due to compounding could be offset by an increased risk of ranibizumab-related endophthalmitis at a different point in the preinjection life of the drug. It may be that drawing ranibizumab into a syringe at the time of injection may somehow increase exposure to bacteria.

Culture-negative endophthalmitis is a different issue. We found an increased risk of culture-negative endophthalmitis with bevacizumab when considering prospective and retrospective data together. Clusters of sterile endophthalmitis associated with intraocular injections of bevacizumab have been reported, although the causes of these outbreaks are not always clear. Fielden et al reported multiple cases of sterile endophthalmitis associated with bevacizumab, where the lot responsible showed higher levels of endotoxin and two silicone-oil residues compared with a control sample.[@b18-opth-9-773] The measurements still met specifications for intravenous use however. Yamashiro et al described another cluster of cases related to a batch of bevacizumab that they speculated may have been caused by contaminating endotoxin.[@b14-opth-9-773] Wickremasinghe et al also reported sterile endophthalmitis with bevacizumab, and suggested a number of possible mechanisms, including endotoxins, increased immune sensitization with multiple injections, and compromised storage of the drug.[@b15-opth-9-773] The increased risk of culture-negative endophthalmitis with bevacizumab was not confirmed when using prospective data alone in this study.

There was no difference in overall endophthalmitis risk associated with the reporting of any perioperative factors studied, including the reported use of povidone iodine, antibiotics, a lid speculum, or an operating suite. Because omitting factors from publication is not equivalent to omitting the techniques themselves in practice, these data cannot be taken to mean that the factors are conclusively unimportant in determining the risk of endophthalmitis.

This study did not show a difference in endophthalmitis risk either, based on the reporting of mask use for the operating physician. McCannel[@b19-opth-9-773] suggested that there may be contamination of the surgical site or instruments by oropharyngeal flora, and Wen et al subsequently showed that speaking while above a blood agar culture plate produces more bacterial colonies than speaking while wearing a surgical mask.[@b20-opth-9-773] This was also found by Simunovic et al[@b21-opth-9-773] and Chen et al[@b22-opth-9-773] who found an increase in streptococcal endophthalmitis following intravitreal injections compared with following cataract surgery. It is possible that the mask use reported does not reflect mask use in practice, leading to a discrepancy between these studies and the current study. Alternatively, this study may lack the statistical power to confirm an association with mask use and endophthalmitis, given the lack of injections given with a mask.

Culture-positive endophthalmitis was significantly increased by the reported use of antibiotics. It is impossible to say that the use of antibiotics results in a higher risk of endophthalmitis, because it is unknown how prevalent antibiotic use was in studies where it was not reported. Bhavsar et al[@b23-opth-9-773] with the Diabetic Retinopathy Clinical Research Network, and Cheung et al[@b24-opth-9-773] reported higher though not statistically different incidences of endophthalmitis in patients receiving antibiotics. Bhatt et al found no difference in endophthalmitis occurrence regardless of antibiotic use.[@b25-opth-9-773] It has been shown that repeated exposure to ophthalmic antibiotics selects for resistant strains of ocular and nasopharyngeal flora,[@b26-opth-9-773] and that drug-resistant strains may be more virulent.[@b27-opth-9-773]

Intravitreal injections given in the US are predominantly given in the office with substerile techniques. This is in contrast to the practice in much of Europe, where these injections are administered in an operating room. Abell et al found that endophthalmitis occurrence in a single practice was lower for injections performed in the operating room versus those performed in an office setting.[@b28-opth-9-773] Because few studies reported using an operating room for injections, we used endophthalmitis occurrence in Europe versus those in the US as a surrogate. Total, culture-positive, and culture-negative endophthalmitis cases between the two regions were not statistically different using the random-effect model, with culture-positive endophthalmitis risk being nearly identical.

This study is not without flaws. As with any meta-analysis or review, the data can only be as good as the studies included. An ideal meta-analysis will include studies of good-quality, typically randomized controlled trials, which have similar inclusion and exclusion criteria and compare treatment arms directly to one another.[@b29-opth-9-773] Because of the scarcity of such data involving bevacizumab and ranibizumab, and the rarity of endophthalmitis, such an approach for the problem of endophthalmitis is not practical. For example, assuming an endophthalmitis risk of 0.05%, one would need 100,000 injections in each group to detect a halving of this risk or 50,000 injections in each group to detect a doubling. In order to have sufficient statistical power, other types of studies must be included in an analysis of endophthalmitis. The studies included here incorporate retrospective data, heterogeneous groups, and small cohorts, all of which can introduce bias. On the other hand, endophthalmitis is somewhat unique in that there are relatively few known risk factors, unlike classic multifactorial diseases, such as AMD or coronary artery disease.

The studies included seldom reported information about how the intravitreal injections were administered. Additionally, the reporting of failure to utilize a perioperative technique is exceedingly rare. This is problematic when concluding whether certain factors alter the risk of endophthalmitis. For this reason, it is important that studies report operative techniques. It is exceedingly difficult to undertake a prospective study with 50,000--100,000 patients per arm, and thus retrospective analysis may be necessary to help answer these questions. Only English-language studies were evaluated, which also may have resulted in sampling error. We did not consider pediatric cases or papers with fewer than five patients either. It is also possible that adverse events may be reported more readily with one drug versus another. Despite the potential pitfalls, the statistical power obtained from including almost 450,000 injections may make the current analysis beneficial in suggesting modifiable factors that contribute to postinjection endophthalmitis.

Conclusion
==========

Endophthalmitis risk was significantly higher in eyes treated with bevacizumab than with ranibizumab, because of a higher risk of culture-negative endophthalmitis in the bevacizumab group. The risk of endophthalmitis for both drugs was similar in prospective analysis. The results of this study suggest that bevacizumab may result in a slightly higher number of culture-negative endophthalmitis cases of unknown cause, but that bacterial or fungal contamination during the processing of bevacizumab likely does not significantly alter the risk of endophthalmitis when considering the vast number of injections given without incident. This study also suggests that antibiotic use postinjection may increase endophthalmitis occurrence.

Supplementary materials
=======================

###### 

Endophthalmitis risk by year.

###### 

Number of intravitreal injections by region/country

                               Bevacizumab   Ranibizumab   Total
  ---------------------------- ------------- ------------- ---------
  Asia                         0             979           979
  Australia                    3,040         2,624         5,664
  Austria                      3,514         4,095         7,609
  Belgium                      120           178           298
  Bosnia and Herzegovina       225           0             225
  Brazil                       444           20            464
  Canada                       8,756         11,188        19,944
  People's Republic of China   3,678         717           4,395
  Croatia                      142           36            178
  Czech Republic               90            0             90
  Denmark                      106           7,990         8,096
  Egypt                        281           225           506
  Europe                       91            1,701         1,792
  France                       1,361         4,456         5,817
  Germany                      5,444         844           6,288
  Greece                       1,589         1,869         3,458
  India                        1,603         376           1,979
  Iran                         6,946         0             6,946
  Ireland                      188           0             188
  Israel                       2,828         0             2,828
  Italy                        2,600         1,348         3,948
  Japan                        5,507         20,840        26,347
  Jordan                       60            0             60
  Lebanon                      1,534         179           1,713
  Mexico                       0             91            91
  Nepal                        196           0             196
  Netherlands                  1,794         0             1,794
  North America                12,585        14,320        26,905
  Norway                       0             65            65
  Oman                         17            0             17
  Poland                       232           162           394
  Portugal                     503           662           1,165
  Saudi Arabia                 11            0             11
  Singapore                    29            183           212
  Slovenia                     760           0             760
  South Korea                  6,223         2,213         8,436
  Spain                        2,739         6,586         9,325
  Sweden                       538           1,665         2,203
  Switzerland                  3,807         41,873        45,680
  Taiwan                       746           100           846
  Thailand                     29            76            105
  Tunisia                      267           0             267
  Turkey                       5,808         626           6,434
  UK                           4,688         8,982         13,670
  US                           78,819        94,172        172,991
  Multiple                     6,186         37,938        44,124

**Notes:** Multicenter trials involving countries from a single continent are grouped by region. Multicenter trials involving countries from multiple continents are grouped under "Multiple".

Statistics were performed by Christina Pinkston, MS, biostatistician with the University of Louisville Statistical Consulting Center. The work was supported in part by an unrestricted grant from Research to Prevent Blindness, New York, NY, USA.
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###### 

Indications for intravitreal injections

                          Bevacizumab   Ranibizumab   Total
  ----------------------- ------------- ------------- ---------
  exAMD                   32,153        82,100        114,253
  PED                     118           356           474
  PCV                     1,286         2,885         4,171
  RAP                     376           620           996
  CNVM (PD)               32            0             32
  CNVM (myopia)           2,607         1,353         3,960
  CNVM (POHS)             1,259         155           1,414
  CNVM (inflammatory)     488           0             488
  CNVM (AS)               330           329           659
  CNVM (PIC)              27            15            42
  CNVM (MCP)              82            0             82
  CNVM (idiopathic)       170           56            226
  CNVM (various)          112           203           315
  DME                     5,566         13,109        18,675
  CME (post ERM peel)     12            0             12
  CME (uveitic)           146           26            172
  CME (PCIOL)             79            0             79
  CME (RP)                0             15            15
  CRVO                    2,183         1,214         3,397
  BRVO                    3,622         2,291         5,913
  RVO                     1,097         544           1,641
  RAM                     16            0             16
  PDR                     757           20            777
  NVI (PDR)               12            0             12
  NVI (various)           57            0             57
  CSR                     101           72            173
  FMVD                    0             126           126
  IMT                     77            180           257
  Radiation retinopathy   431           0             431
  NAION                   17            0             17
  NVG                     0             71            71
  Various                 122,911       163,639       286,550

**Abbreviations:** exAMD, exudative age-related macular degeneration; PED, pigment epithelial detachment; PCV, polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation; CNVM, choroidal neovascular membrane; PD, pattern dystrophy; POHS, presumed ocular histoplasmosis syndrome; AS, angioid streaks; PIC, punctate inner choroidopathy; MCP, multifocal choroiditis and panuveitis; DME, diabetic macular edema; CME, cystoid macular edema; ERM, epiretinal membrane; PCIOL, posterior chamber intraocular lens; RP, retinitis pigmentosa; CRVO, central retinal vein occlusion; BRVO, branch RVO; RAM, retinal arterial macroaneurysm; PDR, proliferative diabetic retinopathy; NVI, neovascularization of the iris; CSR, central serous chorioretinopathy; FMVD, foveomacular vitelliform dystrophy; IMT, idiopathic macular telangiectasia; NAION, nonarteritic ischemic optic neuropathy; NVG, neovascular glaucoma.

###### 

Percentage of papers positively reporting specific perioperative techniques

  -----------------------------------------------------------------------------------------------------
                    Bevacizumab   Ranibizumab   RR[a](#tfn2-opth-9-773){ref-type="table-fn"} (95% CI)
  ----------------- ------------- ------------- -------------------------------------------------------
  Povidone iodine   69.00%        52.30%        1.00 (0.99--1.01)\
                                                *P*=0.9617

  Antibiotics       50.90%        48.00%        0.96 (0.94--0.97)\
                                                *P*\<0.0001

  Lid speculum      33.70%        24.00%        1.00 (0.98--1.02)\
                                                *P*=0.9617

  Mask              6.80%         6.30%         1.00 (0.96--1.05)\
                                                *P*=0.9786

  Operating room    7.00%         3.80%         1.00 (0.94--1.08)\
                                                *P*=0.9308
  -----------------------------------------------------------------------------------------------------

**Notes:**

Calculated with the random-effect model with Wald *P*-values comparing the reporting between drugs. Percentages are the proportion of injections for which the technique was positively reported.

**Abbreviations:** RR, relative risk; CI, confidence interval.

###### 

Overall occurrence of postinjection endophthalmitis cases by perioperative technique

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           Injections   Cases   Risk[c](#tfn6-opth-9-773){ref-type="table-fn"} (%)   Relative risk[d](#tfn7-opth-9-773){ref-type="table-fn"} (95% CI)
  -------------------------------------------------------- ------------ ------- ---------------------------------------------------- ------------------------------------------------------------------
  **Povidone iodine**                                                                                                                

  Reported[a](#tfn4-opth-9-773){ref-type="table-fn"}       262,361      105     0.040%                                               

  Not reported[b](#tfn5-opth-9-773){ref-type="table-fn"}   183,142      77      0.042%                                               1.09 (0.60--1.99)\
                                                                                                                                     *P*=0.7594

  **Antibiotic**                                                                                                                     

  Reported                                                 218,975      94      0.043%                                               

  Not reported                                             226,528      88      0.039%                                               0.67 (0.43--1.05)\
                                                                                                                                     *P*=0.0690

  **Speculum**                                                                                                                       

  Reported                                                 124,052      55      0.044%                                               

  Not reported                                             321,451      127     0.040%                                               0.74 (0.39--1.38)\
                                                                                                                                     *P*=0.3137

  **Mask**                                                                                                                           

  Reported                                                 28,799       4       0.014%                                               

  Not reported                                             416,704      178     0.043%                                               2.39 (0.62--9.31)\
                                                                                                                                     *P*=0.1487

  **Operating room**                                                                                                                 

  Reported                                                 22,564       5       0.022%                                               

  Not reported                                             422,939      177     0.042%                                               2.30 (0.64--8.36)\
                                                                                                                                     *P*=0.1358
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Perioperative technique was reported to be used;

perioperative technique was either not used or use was unspecified;

risk of developing endophthalmitis;

relative risk calculated with random-effect model with Wald *P*-values.

**Abbreviation:** CI, confidence interval.

###### 

Occurrence of culture-positive postinjection endophthalmitis cases

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                            Injections   Cases   Risk[c](#tfn11-opth-9-773){ref-type="table-fn"} (%)   Relative risk[d](#tfn12-opth-9-773){ref-type="table-fn"} (95% CI)
  --------------------------------------------------------- ------------ ------- ----------------------------------------------------- -------------------------------------------------------------------
  **Drug**                                                                                                                             

  Ranibizumab                                               269,379      24      0.011%                                                

  Bevacizumab                                               176,124      30      0.017%                                                1.11 (0.55--2.26)\
                                                                                                                                       *P*=0.7512

  **Year of publication**                                                                                                              

  2013                                                      181,630      15      0.008%                                                1.00 (reference)

  2012                                                      67,727       7       0.013%                                                2.11 (0.23--19.59)

  2011                                                      34,684       3       0.011%                                                1.98 (0.16--24.00)

  2010                                                      41,989       4       0.010%                                                2.87 (0.26--31.54)

  2009                                                      47,268       8       0.028%                                                5.11 (0.63--41.15)

  2008                                                      56,636       15      0.030%                                                7.88 (0.94--66.01)

  2007                                                      3,832        2       0.066%                                                14.60 (1.01--209.52)

  2006                                                      11,737       0       0                                                     0\
                                                                                                                                       *P*=0.2556

  **Study type**                                                                                                                       

  Prospective                                               109,541      7       0.010%                                                

  Retrospective                                             335,962      47      0.014%                                                2.89 (0.49--16.97)\
                                                                                                                                       *P*=0.1060

  **Povidone iodine**                                                                                                                  

  Reported[a](#tfn9-opth-9-773){ref-type="table-fn"}        262,361      42      0.016%                                                

  Not reported[b](#tfn10-opth-9-773){ref-type="table-fn"}   183,142      12      0.007%                                                0.55 (0.12--2.40)\
                                                                                                                                       *P*=0.3153

  **Antibiotic**                                                                                                                       

  Reported                                                  218,975      41      0.019%                                                

  Not reported                                              226,528      13      0.006%                                                0.37 (0.14--0.94)\
                                                                                                                                       *P*=0.0207

  **Speculum**                                                                                                                         

  Reported                                                  124,052      25      0.021%                                                

  Not reported                                              321,451      29      0.009%                                                0.35 (0.09--1.39)\
                                                                                                                                       *P*=0.0778

  **Mask**                                                                                                                             

  Reported                                                  28,799       0       0                                                     --

  Not reported                                              416,704      54      0.013%                                                --

  **Operating room**                                                                                                                   

  Reported                                                  22,564       0       0                                                     --

  Not reported                                              422,939      54      0.013%                                                --
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Perioperative technique was reported to be used;

perioperative technique was either not used or use was unspecified;

risk of endophthalmitis adjusted for the difference in culture rates between groups;

random-effect model with Wald *P*-values.

**Abbreviation:** CI, confidence interval.

###### 

Occurrence of culture-negative postinjection endophthalmitis cases

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                            Injections   Cases   Risk[c](#tfn16-opth-9-773){ref-type="table-fn"} (%)   Relative risk[d](#tfn17-opth-9-773){ref-type="table-fn"} (95% CI)
  --------------------------------------------------------- ------------ ------- ----------------------------------------------------- -------------------------------------------------------------------
  **Drug**                                                                                                                             

  Ranibizumab                                               269,379      33      0.015%                                                

  Bevacizumab                                               176,124      64      0.036%                                                2.12 (1.26--3.57)\
                                                                                                                                       *P*=0.0026

  **Year of publication**                                                                                                              

  2013                                                      181,630      36      0.020%                                                1.00 (reference)

  2012                                                      67,727       17      0.032%                                                1.16 (0.16--8.16)

  2011                                                      34,684       4       0.014%                                                0.38 (0.03--5.45)

  2010                                                      41,989       25      0.062%                                                1.45 (0.15--13.66)

  2009                                                      47,268       4       0.014%                                                0.74 (0.07--7.52)

  2008                                                      56,636       6       0.012%                                                0.81 (0.07--72.63)

  2007                                                      3,832        1       0.033%                                                1.83 (0.05--72.63)

  2006                                                      11,737       4       0.040%                                                2.07 (0.05--87.13)\
                                                                                                                                       *P*=0.9266

  **Study type**                                                                                                                       

  Prospective                                               109,541      14      0.021%                                                

  Retrospective                                             335,962      83      0.025%                                                1.89 (0.41--8.72)\
                                                                                                                                       *P*=0.2787

  **Povidone iodine**                                                                                                                  

  Reported[a](#tfn14-opth-9-773){ref-type="table-fn"}       262,361      48      0.018%                                                

  Not reported[b](#tfn15-opth-9-773){ref-type="table-fn"}   183,142      49      0.029%                                                1.46 (0.36--5.90)\
                                                                                                                                       *P*=0.4948

  **Antibiotic**                                                                                                                       

  Reported                                                  218,975      40      0.018%                                                

  Not reported                                              226,528      57      0.027%                                                0.64 (0.32--1.29)\
                                                                                                                                       *P*=0.1844

  **Speculum**                                                                                                                         

  Reported                                                  124,052      20      0.016%                                                

  Not reported                                              321,451      77      0.024%                                                0.84 (0.19--3.82)\
                                                                                                                                       *P*=0.7806

  **Mask**                                                                                                                             

  Reported                                                  28,799       2       0.012%                                                

  Not reported                                              416,704      95      0.023%                                                1.36 (0.09--2.06)\
                                                                                                                                       *P*=0.0868

  **Operating room**                                                                                                                   

  Reported                                                  22,564       1       0.019%                                                

  Not reported                                              422,939      96      0.023%                                                4.08 (0.11--156.18)\
                                                                                                                                       *P*=0.2415
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Perioperative technique was reported to be used;

perioperative technique was either not used or use was unspecified;

risk of endophthalmitis adjusted for the difference in culture rates between groups;

random-effect model with Wald *P*-values.

**Abbreviation:** CI, confidence interval.

###### 

Endophthalmitis risk in the US and Europe

  -----------------------------------------------------------------------------------------------------------------------------------------
                                                               US        Europe    RR (95% CI)[a](#tfn19-opth-9-773){ref-type="table-fn"}
  ------------------------------------------------------------ --------- --------- --------------------------------------------------------
  **Injections**                                               172,991   119,477   

  Endophthalmitis cases                                        80        33        

  Risk[b](#tfn20-opth-9-773){ref-type="table-fn"}              0.046%    0.028%    1.25 (0.44--3.52)\
                                                                                   *P*=0.5402

  Cases cultured                                               96.25%    63.64%    

  **Culture-positive cases**                                   22        8         

  Culture^+^ risk[b](#tfn20-opth-9-773){ref-type="table-fn"}   0.013%    0.007%    1.94 (0.24--15.74)\
                                                                                   *P*=0.3868

  Normalized risk[c](#tfn21-opth-9-773){ref-type="table-fn"}   0.013%    0.010%    --

  **Culture-negative cases**                                   55        13        

  Culture^−^ risk[b](#tfn20-opth-9-773){ref-type="table-fn"}   0.032%    0.011%    2.05 (0.44--9.49)\
                                                                                   *P*=0.2323

  Normalized risk[c](#tfn21-opth-9-773){ref-type="table-fn"}   0.032%    0.016%    --
  -----------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Random-effect model with Wald *P*-values comparing the risk of endophthalmitis between geographic areas (it is not possible to use this model with normalized risks);

occurrence of endophthalmitis;

risk of endophthalmitis adjusted for the difference in culture rates between groups.

**Abbreviations:** RR, relative risk; CI, confidence interval.

###### 

Organisms identified from culture-positive endophthalmitis

                                        Bevacizumab   Ranibizumab
  ------------------------------------- ------------- -------------
  Total endophthalmitis                 103           79
  Cultured                              94            57
  No growth                             64            33
  *Staphylococcus epidermidis*          4             6
  Coagulase-negative *Staphylococcus*   8             1
  *Staphylococcus* aureus               2             1
  Total *Staphylococcus* spp.           14            8
  *Streptococcus viridans*              1             2
  *Streptococcus salivarius*            0             1
  *Streptococcus oralis*                1             0
  *Streptococcus mitis*                 0             1
  *Streptococcus* (unspecified)         2             1
  Total *Streptococcus* spp.            4             5
  *Enterococcus faecalis*               1             0
  *Haemophilus influenzae*              1             0
  *Haemophilus* (unspecified)           1             0
  Unknown organism                      5             11
  *Propionibacterium acnes*             2             0

###### 

Factors influencing the risk of postinjection endophthalmitis (prospective data)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                            Injections   Cases   Risk[c](#tfn25-opth-9-773){ref-type="table-fn"} (%)   Relative risk[d](#tfn26-opth-9-773){ref-type="table-fn"} (95% CI)
  --------------------------------------------------------- ------------ ------- ----------------------------------------------------- -------------------------------------------------------------------
  **Drug**                                                                                                                             

  Ranibizumab                                               114,135      51      0.045%                                                

  Bevacizumab                                               36,742       13      0.035%                                                0.62 (0.29--1.32)\
                                                                                                                                       *P*=0.1740[e](#tfn27-opth-9-773){ref-type="table-fn"}

  **Year of publication**                                                                                                              

  2013                                                      22,932       8       0.035%                                                1.00 (reference)

  2012                                                      53,610       28      0.052%                                                1.21 (0.43--3.37)

  2011                                                      18,454       2       0.011%                                                0.29 (0.05--1.68)

  2010                                                      8,848        3       0.034%                                                0.70 (0.14--3.52)

  2009                                                      29,202       10      0.034%                                                0.76 (0.21--2.74)

  2008                                                      4,175        1       0.024%                                                0.57 (0.05--6.13)

  2007                                                      1,330        1       0.075%                                                1.97 (0.19--20.17)

  2006                                                      12,326       11      0.089%                                                3.71 (1.02--13.49)\
                                                                                                                                       *P*=0.1212[e](#tfn27-opth-9-773){ref-type="table-fn"}

  **Povidone iodine**                                                                                                                  

  Reported[a](#tfn23-opth-9-773){ref-type="table-fn"}       47,001       22      0.047%                                                

  Not reported[b](#tfn24-opth-9-773){ref-type="table-fn"}   103,876      42      0.040%                                                0.95 (0.39--2.30)\
                                                                                                                                       *P*=0.8996

  **Antibiotic**                                                                                                                       

  Reported                                                  42,550       22      0.052%                                                

  Not reported                                              108,327      42      0.039%                                                0.70 (0.30--1.64)\
                                                                                                                                       *P*=0.4060

  **Speculum**                                                                                                                         

  Reported                                                  32,173       16      0.050%                                                

  Not reported                                              118,704      48      0.040%                                                0.70 (0.24--2.00)\
                                                                                                                                       *P*=0.4753

  **Mask**                                                                                                                             

  Reported                                                  4,689        0       0                                                     --

  Not reported                                              146,188      64      0.044%                                                --

  **Operating room**                                                                                                                   

  Reported                                                  6,585        0       0                                                     --

  Not reported                                              144,292      64      0.044%                                                --

  **Culture-positive cases**                                                                                                           

  Bevacizumab                                               114,135      0       0                                                     --

  Ranibizumab                                               36,742       12      0.033%                                                --

  **Culture-negative cases**                                                                                                           

  Bevacizumab                                               114,135      4       0.004%                                                

  Ranibizumab                                               36,742       14      0.038%                                                0.16 (0.00--4.32)\
                                                                                                                                       *P*=0.1436
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Perioperative technique was reported to be used;

perioperative technique was either not used or use was unspecified;

occurrence of endophthalmitis;

random-effect model with Wald *P*-values except where indicated;

log-likelihood comparison.

**Abbreviation:** CI, confidence interval.
